Small molecule compound, anti-aging preparation formed by small molecule compound and application

By using curcumin, phroscolin and small-molecular compounds combined with exosomes or liposome carriers formed by extrusion of human mesenchymal stem cells, early development-related transcription factors are activated, and human cells, tissues, and organs are solved. The safety and effectiveness of aging achieves the extension of cell telomeres length and overall aging reversal, improving health status and quality of life.

CN119033724APending Publication Date: 2024-11-29李立楷
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411134941.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing technology is difficult to find safe and effective ways to delay or reverse the aging process of human cells, tissues, and organs, especially due to the safety and feasibility of genetically modified technology in the human body, and the research on the combination of small molecule compounds in the field of anti-aging Fewer, screening and application are difficult.

Method used

SOX2 or Klf4 messenger cRNA loaded with exosomes or liposome carriers formed by extrusion of curcumin, fuscolin and human mesenchymal stem cells, is regulated by epigenetics. and activating transcription factors related to early development to prevent, delay or reverse cellular senescence.

Benefits of technology

This small molecule compound combination can safely and effectively extend the telomere length of cells, instantly stimulate the expression of telomere-related proteins, avoid the continuous expression of stem genes, realize the overall aging reversal of cells, tissues, and organs, and is easy to control and produce on a large scale. Improve health and quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033724A_ABST
    Figure CN119033724A_ABST
Patent Text Reader

Abstract

The invention discloses a small molecule compound, an anti-aging preparation formed by the small molecule compound and application of the anti-aging preparation. Wherein the small molecule compound comprises the following components in parts by weight: 2-4 parts of curcumin, 1-2 parts of forskolin and 96-98 parts of a messenger carrier; the messenger vector comprises an exosome-like body or a liposome formed by extruding human mesenchymal stem cells, and messenger cRNA of SOX2 or messenger cRNA of Klf4, and the messenger cRNA of SOX2 or the messenger cRNA of Klf4 is loaded in the exosome-like body or the liposome formed by extruding the human mesenchymal stem cells. According to the present invention, the epigenetically regulation is performed on the aged or senescent cells, or the early development-related transcription factors are activated, such that the prevention, the delay or the reversion of the cell senescence is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of cell biology, and specifically relates to small molecule compounds and the formation and application of anti-aging preparations. Background Art

[0002] The aging of the human body is a major health problem in modern society and the main cause of most geriatric diseases. The aging process is accompanied by a decline in body function, a weakening of the ability to adapt to external changes, and a decline in compensatory function, which ultimately induces a variety of diseases. For example, cardiovascular disease, malignant tumors, degenerative diseases of the nerves, internal organs, bones and muscles, and diabetes are closely related to aging. For every 10 years of age, the mortality rate due to cardiovascular disease increases by 2 to 3 times. It can be seen that aging has a huge impact on the quality of human life and health status.

[0003] At present, factors related to aging (such as aging-related genes) and anti-aging drugs and methods are constantly being reported. For example, in 2016, the research team of the Mayo Clinic in the United States extended the lifespan of mice by more than 20% by removing senescent cells; different research institutions have found that feeding mice with rapamycin, coenzyme I, NMN (nicotinamide mononucleotide), spermidine, etc. can significantly extend the lifespan of mice; a research institution has used a nematode model to reveal the association between RNA splicing function and longevity; another research institution has reported that the reactivation of HOXA9 in old age will limit the regeneration of skeletal muscle, and the activation of NRF2 is beneficial to anti-aging; in addition, according to relevant reports, removing mutated DNA in mitochondria, or adjusting living habits and lifestyles such as running and dieting also have a positive effect on delaying aging.

[0004] Although the above substances or methods have the effect of improving the health of organs and thus increasing lifespan, given the complexity of the aging process at the cell, tissue, and organ levels, people's understanding of the aging process and its mechanisms is still limited, and the effects of the above methods and substances for delaying aging are still uncertain. In December 2016, researchers at the Salk Institute restored many organs of progeria mice to a relatively healthy and youthful state by highly expressing the four Yamanaka factors (the four factors for preparing induced pluripotent stem cells) in living mice, and extended the lifespan of the mice by 1 / 3.

[0005] Therefore, methods or substances used to delay or reverse the aging process of most cells or tissues and organs in the body, if their effects are clear and the process is controllable, are expected to become a reliable technical basis for human anti-aging.

[0006] Although transgenic technology has reversed the aging of most organs in progeria mice, this method is not feasible in humans due to safety concerns. In addition, the activation of the four Yamanaka factors used has the risk of tumorigenesis. Therefore, it is necessary to find safe and effective modes of action and substances that can be used in humans.

[0007] Small molecule compounds or combinations of small molecule compounds have the following advantages: ① No exogenous transcription factors are introduced, the genetic structure of the source cells is not changed, and they have good safety and stability; ② The action system is relatively stable, easy to control, and low cost; ③ The action process is short, the efficiency is high, and it is easy to mass produce; ④ It is easy for the human body to absorb and metabolize, and will become an effective substance to slow down or reverse the aging process. However, there are few reports and studies on the anti-aging effects of small molecule compounds or combinations of small molecule compounds. On the one hand, there is a lack of methods and systems for screening such small molecule compounds; on the other hand, even if useful small molecule compounds are tried on mice, due to the approximately 25% genetic difference between humans and mice, the feasibility of applying them to similar cells in humans is not high. Therefore, targeted screening of small molecule compounds that can safely and clearly delay or reverse the human aging process is of great significance for delaying the human aging process, improving health status and quality of life. Summary of the invention

[0008] In view of the above technical problems, the present invention provides a small molecule compound that prevents, delays or reverses cell senescence by epigenetically regulating aged or senescent cells or by activating transcription factors related to early development.

[0009] In order to achieve the above purpose, this application adopts the following technical solutions:

[0010] A small molecule compound comprises the following components in weight fractions: 2-4 parts of curcumin, 1-2 parts of forskolin, and 96-98 parts of a messenger carrier; the messenger carrier comprises an exosome-like substance or a liposome formed by extruding human mesenchymal stem cells, and a messenger cRNA of SOX2 or a messenger cRNA of Klf4, wherein the messenger cRNA of SOX2 or the messenger cRNA of Klf4 is loaded inside the exosome-like substance or the liposome formed by extruding human mesenchymal stem cells.

[0011] Furthermore, the weight ratio of curcumin to forskolin is 2:1.

[0012] Furthermore, the human mesenchymal stem cells include human adipose-derived mesenchymal stem cells, human umbilical cord-derived mesenchymal stem cells or human bone marrow-derived mesenchymal stem cells.

[0013] Furthermore, the CDS sequence of the messenger cRNA of SOX2 is shown in SEQ ID NO.1.

[0014] Furthermore, the CDS sequence of the Klf4 messenger cRNA is shown in SEQ ID NO.2.

[0015] An anti-aging preparation comprises a small molecule compound as described above.

[0016] Furthermore, the preparation includes one or more of a preparation box, a culture solution, a culture medium, a medicine, a health product, a food, a cosmetic, and a medical device containing the small molecule compound.

[0017] An application of a small molecule compound, using the small molecule compound as described above to improve the tissue and organ repair ability of mammals.

[0018] An application of a small molecule compound, using the small molecule compound as described above to reverse the aging process of cells, tissues and organs of mammals.

[0019] An application of a small molecule compound, using the small molecule compound as described above to increase the telomere length of mammalian cells.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The small molecule compound of the present application is characterized in that it includes the following components in weight fractions: 2-4 parts of curcumin, 1-2 parts of forskolin, and 96-98 parts of a messenger carrier; the messenger carrier includes exosomes or liposomes formed by extrusion of human mesenchymal stem cells, messenger cRNA of SOX2 or messenger cRNA of Klf4, wherein the messenger cRNA of SOX2 or messenger cRNA of Klf4 is loaded inside the exosomes or liposomes formed by extrusion of human mesenchymal stem cells. The exosomes or liposomes formed by extrusion of human mesenchymal stem cells have the same components as the cell structure, can easily penetrate the cell shell and enter the cell, and after entering the cell, the exosomes or liposomes will dissolve, so that the messenger cRNA of SOX2 or messenger cRNA of Klf4 loaded inside it is released, and synergistically acts with curcumin and forskolin to act together inside the cell. The small molecule compound combination of the present application can be used to extend the telomere length of cells of mammals such as humans, transiently stimulate the expression / upregulation of telomere-related proteins, such as TERT (telomerase reverse transcriptase) and TPP1, and will not stimulate the expression of stemness genes in cells of mammals such as humans. It is safe and effective.

[0022] The present application prevents, delays or reverses cell senescence by epigenetically regulating aged or senescent cells or by activating transcription factors associated with early development.

[0023] This application uses small molecule compounds or their combinations to reverse the aging of cells, tissues, organs, and organisms, prolong the length of cell telomeres, have clear targets, clear ingredients, mature and stable, and can accurately regulate the anti-aging process; and small molecule compounds are easy to control quality and mass produce. Since the body or cells do not continuously express stemness genes during the action process, they are highly safe; and small molecule compounds and their combinations are easily absorbed by the body, and can prevent, delay, and reverse aging at the overall level of cells, tissues, organs, and organisms, respectively, which is of great significance for delaying the human aging process, improving health status and quality of life. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0026] In the attached figure:

[0027] Figure 1 This is a schematic diagram of the chemical structure of turmeric;

[0028] Figure 2 Schematic diagram of the chemical structure of forskolin. DETAILED DESCRIPTION

[0029] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and essence of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention all belong to the scope of protection of the present invention. Unless otherwise specified, the experimental materials, reagents, instruments, etc. used in the present examples are all commercially available; unless otherwise specified, all technical means in the examples of the present invention are conventional means well known to those skilled in the art.

[0030] The present application provides a small molecule compound, comprising the following components in weight fractions: 2-4 parts of curcumin, 1-2 parts of forskolin, and 96-98 parts of a messenger carrier; the messenger carrier comprises an exosome-like substance or a liposome formed by extrusion of human mesenchymal stem cells, and a messenger cRNA of SOX2 or a messenger cRNA of Klf4, wherein the messenger cRNA of SOX2 or the messenger cRNA of Klf4 is loaded inside the exosome-like substance or the liposome formed by extrusion of human mesenchymal stem cells.

[0031] Wherein, the human mesenchymal stem cells include human adipose-derived mesenchymal stem cells, human umbilical cord-derived mesenchymal stem cells or human bone marrow mesenchymal stem cells. The exosomes or liposomes formed by the extrusion of human mesenchymal stem cells have the same components as the cell structure, and can easily penetrate the cell shell and enter the cell. After entering the cell, the exosomes or liposomes will dissolve, so that the messenger cRNA of SOX2 or the messenger cRNA of Klf4 loaded inside it will be released, and work synergistically with curcumin and forskolin to act together inside the cell.

[0032] The weight ratio of curcumin to forskolin in this application is 2:1. The chemical structure of curcumin is as follows Figure 1 The chemical structure of forskolin is shown in Figure 2 shown.

[0033] The CDS sequence of the messenger cRNA of SOX2 is shown in SEQ ID NO.1, specifically:

[0034] atgt acaacatgat ggagacggag ctgaagccgc cgggcccgca

[0035] gcaaacttcg gggggcggcg gcggcaactc caccgcggcg gcggccggcg gcaaccagaa

[0036] aaacagcccg gaccgcgtca agcggcccat gaatgccttc atggtgtggt cccgcgggca

[0037] gcggcgcaag atggcccagg agaaccccaa gatgcacaac tcggagatca gcaagcgcct

[0038] gggcgccgag tggaaacttt tgtcggagac ggagaagcgg ccgttcatcg acgaggctaa

[0039] gcggctgcga gcgctgcaca tgaaggagca cccggattat aaataccggc cccggcggaa

[0040] aaccaagacg ctcatgaaga aggataagta cacgctgccc ggcgggctgc tggcccccgg

[0041] cggcaatagc atggcgagcg gggtcggggt gggcgccggc ctgggcgcgg gcgtgaacca

[0042] gcgcatggac agttacgcgc acatgaacgg ctggagcaac ggcagctaca gcatgatgca

[0043] ggaccagctg ggctacccgc agcacccggg cctcaatgcg cacggcgcag cgcagatgca

[0044] gcccatgcac cgctacgacg tgagcgccct gcagtacaac tccatgacca gctcgcagac

[0045] ctacatgaac ggctcgccca cctacagcat gtcctactcg cagcagggca cccctggcat

[0046] ggctcttggc tccatgggtt cggtggtcaa gtccgaggcc agctccagcc cccctgtggt

[0047] tacctcttcc tcccactcca gggcgccctg ccaggccggg gacctccggg acatgatcag

[0048] catgtatctc cccggcgccg aggtgccgga acccgccgcc cccagcagac ttcacatgtc

[0049] ccagcactac cagagcggcc cggtgcccgg cacggccatt aacggcacac tgcccctctc

[0050] Acacatgtga

[0051] The CDS sequence of the messenger cRNA of Klf4 is shown in SEQ ID NO.2, specifically:

[0052] atgaggcagccac ctggcgagtc tgacatggct gtcagcgacg cgctgctccc atctttctcc

[0053] acgttcgcgt ctggcccggc gggaagggag aagacactgc gtcaagcagg tgccccgaat

[0054] aaccgctggc gggaggagct ctcccacatg aagcgacttc ccccagtgct tcccggccgc

[0055] ccctatgacc tggcggcggc gaccgtggcc acagacctgg agagcggcgg agccggtgcg

[0056] gcttgcggcg gtagcaacct ggcgccccta cctcggagag agaccgagga gttcaacgat

[0057] ctcctggacc tggactttat tctctccaat tcgctgaccc atcctccgga gtcagtggcc

[0058] gccaccgtgt cctcgtcagc gtcagcctcc tcttcgtcgt cgccgtcgag cagcggccct

[0059] gccagcgcgc cctccacctg cagcttcacc tatccgatcc gggccgggaa cgacccgggc

[0060] gtggcgccgg gcggcacggg cggaggcctc ctctatggca gggagtccgc tccccctccg

[0061] acggctccct tcaacctggc ggacatcaac gacgtgagcc cctcgggcgg cttcgtggcc

[0062] gagctcctgc ggccagaatt ggacccggtg tacattccgc cgcagcagcc gcagccgcca

[0063] ggtggcgggc tgatgggcaa gttcgtgctg aaggcgtcgc tgagcgcccc tggcagcgag

[0064] tacggcagcc cgtcggtcat cagcgtcagc aaaggcagcc ctgacggcag ccacccggtg

[0065] gtggtggcgc cctacaacgg cgggccgccg cgcacgtgcc ccaagatcaa gcaggaggcg

[0066] gtctcttcgt gcacccactt gggcgctgga ccccctctca gcaatggcca ccggccggct

[0067] gcacacgact tccccctggg gcggcagctc cccagcagga ctaccccgac cctgggtctt

[0068] gaggaagtgc tgagcagcag ggactgtcac cctgccctgc cgcttcctcc cggcttccat

[0069] ccccacccgg ggcccaatta cccatccttc ctgcccgatc agatgcagcc gcaagtcccg

[0070] ccgctccatt accaaggtca gtcccgggga tttgtagctc gggctgggga gccctgtgtg

[0071] tgctggcccc acttcgggac acacgggatg atgctcaccc caccttcttc acccctagag

[0072] ctcatgccac ccggttcctg catgccagag gagcccaagc caaagagggg aagacgatcg

[0073] tggccccgga aaaggaccgc cacccacact tgtgattacg cgggctgcgg caaaacctac

[0074] acaaagagtt cccatctcaa ggcacacctg cgaacccaca caggtgagaa accttaccac

[0075] tgtgactggg acggctgtgg atggaaattc gcccgctcag atgaactgac caggcactac

[0076] cgtaaacaca cggggcaccg cccgttccag tgccaaaaat gcgaccgagc attttccagg

[0077] tcggaccacc tcgccttaca catgaagagg catttttaa

[0078] The present application also provides an anti-aging preparation, including a small molecule compound as described above. The specific anti-aging preparation includes one or more of a preparation box, a culture solution, a culture medium, a medicine, a health product, a food, a cosmetic, and a medical device containing the small molecule compound.

[0079] The technical solution of this application is further explained below through specific embodiments:

[0080] Example 1

[0081] 1. Isolation of skin fibroblasts

[0082] 1.1 Skin tissue pieces with a diameter of about 1 cm were obtained from volunteers, and skin fibroblasts were separated by the adherence method. The separated cells were cultured in a basic culture medium, which included 10% fetal bovine serum (Hyclone) + 100 U / ml penicillin (Sigma) + 100 μg / ml streptomycin (Sigma) + high-glucose DMEM.

[0083] 1.2 Cell passage and large-scale expansion. In this experiment, the cells were at the 12th generation. The day before treatment (Day-1), the inoculation cell density was 1-2.5×10 4 / cm 2 Culture in an incubator at 37°C and 5% CO2.

[0084] 2. Small molecule compound treatment of skin fibroblasts

[0085] The basal culture medium was replaced with a small molecule treatment solution, and the cells were cultured for 2-20 days. The small molecule treatment solution refers to: 10% fetal bovine serum (Hyclone) + 100U / ml penicillin (Sigma) + 100μg / ml streptomycin (Sigma) + high-glucose DMEM medium (Gibco) + 2 parts of curcumin, 1 part of forskolin, and 97 parts of a messenger carrier (including exosomes or liposomes formed by extrusion of human mesenchymal stem cells, messenger mRNA of SOX2 and messenger mRNA of Klf4), and the cells were cultured at 37°C and 5% CO2. In this culture system, 10% fetal bovine serum can also be replaced by a serum substitute (invitrogen) at a concentration of 10% to 20%; 100U / ml penicillin (Sigma) and 100μg / ml streptomycin (Sigma) can be omitted.

[0086] 3. Maintenance and culture of skin fibroblasts

[0087] After the treatment in the second step, the basal culture medium is completely replaced, and the culture is maintained normally, and the cells are cultured at 37°C and 5% CO2. The basal culture medium is: 10% fetal bovine serum (Hyclone) + 100U / ml penicillin (Sigma) + 100μg / ml streptomycin (Sigma) + high-glucose DMEM, in which the 10% fetal bovine serum can also be replaced by a serum substitute (invitrogen) at a concentration of 10% to 20%; 100U / ml penicillin (Sigma) and 100μg / ml streptomycin (Sigma) can be omitted.

[0088] 4. Identification of cell characteristics after treatment

[0089] 4.1 When the cells were passaged to passage 14, the cells were stained and identified using the Bio-Tech Cell Senescence β-galactosidase Staining Kit.

[0090] 4.2 When the cells were passaged to passage 14, they were stained with CD29-PE flow cytometry antibody from ebioscience, and the isotype control from the same manufacturer was used as a control. The analysis was performed on a BD JAZZ flow cytometer according to the manufacturer's instructions.

[0091] 4.3 When the cells were passaged to the 14th generation, they were cultured in a 24-well plate and fixed with 4% PFA for 10 minutes. Then, they were stained with Santa Cruz Vimentin antibody according to the immunofluorescence procedure.

[0092] 4.4 Cell proliferation detection, with 1.5x10 5 As the initial inoculum cell amount, cells were counted for 12 consecutive days, and each time point was repeated for 3 groups.

[0093] 4.5 When the cells were passaged to the 14th generation, DNA samples were collected and telomere length was detected using the Cawthon qPCR method, with Takara SYBR Green I as the fluorescent dye.

[0094] The telomere amplification primer sequences are

[0095] mTe1:CGGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT;

[0096] mTe1:GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT;

[0097] Single copy gene primers

[0098] 36B4-SF:CAGCAAGTGGGAAGGTGTAATCC;

[0099] 36B4-SR:CCATTCTATCATCAACGGGTACAA.

[0100] 4.6 When the cells were passaged to the 14th generation, RNA samples were collected and TERT was detected by PCR. The primer sequence of human TERT was

[0101] F:5'-CGGAAGAGTGTCTGGAGCAA-3;

[0102] R5′-GGATGAAGCGGAGTCTGGA-3′.

[0103] 4.7 When the cells were passaged to the 14th generation, RNA samples were collected, and the changes in the expression levels of genes TPP1, CDKN1A, ATF3, GADD45B, BTG2, H2AFX, ITGA6, and COL1A1 were quantified through transcriptome analysis.

[0104] 4.8 Allogeneic skin transplantation, detection of the immunomodulatory effect of human skin fibroblast culture fluid treated with small molecule compounds. The specific method is as follows: the experimental groups are small molecule compound treated cell group, untreated cell group, and PBS group. Among them, the 14th generation was subcultured and the animal experiment was performed in accordance with the requirements of the Animal Ethics Committee. The donor C57B / 6 mice were anesthetized, fixed in the supine position, and the whole back was depilated. The full layer of skin of 1.5cm x 1.5cm was taken from the back, and the subcutaneous fat and blood vessels were removed. The mouse skin was cut into skin pieces with a diameter of 1.0cm and placed in a plate containing sterile PBS for later use. The cut skin pieces were turned over and placed in a culture dish with saline. The subcutaneous tissue was gently cut to the dermis with a surgical blade, and then placed in sterile saline for later use.

[0105] The recipients were BALB / c mice. After anesthesia, the back hair was removed, the back skin was disinfected with iodine, a skin incision with a diameter of 1.0 cm was prepared, and the blood vessels were preserved. C57B / 6 skin grafts were transplanted in the reverse direction of the back hair, and the surface was covered with vaseline gauze and bandages with appropriate tightness. Within 1 hour after transplantation, the liquids of each group in the list were injected from the tail vein.

[0106] 4.9 Detection of cell clone formation rate: After the cells were subcultured to the 14th generation, cells in the logarithmic growth phase were selected and counted at 10 cells / cm 2 Plate the plates, set up 3 replicate wells for each group, change the medium every 2 days, stain with Giemsa or PI after 1 to 2 weeks, and count the number of clones formed under a microscope.

[0107] The operation of Example 1 was repeated 5 times to obtain 5 results, namely, the first Example 1, the second Example 1, the third Example 1, the fourth Example 1 and the fifth Example 1.

[0108] Example 2

[0109] 1. Culture of bone marrow mesenchymal stem cells

[0110] 1.1 Commercial human bone marrow mesenchymal stem cells were purchased or mesenchymal stem cells were isolated from the bone marrow of volunteers with bone fragments after bone trauma. The cells were cultured in a basic culture medium, which included 8% fetal bovine serum (Hyclone) + 100 U / ml penicillin (Sigma) + 100 μg / ml streptomycin (Sigma) + low-glucose DMEM.

[0111] 1.2 Cell passage and large-scale expansion. In this experiment, the cells were at the 10th generation. The day before treatment (Day-1), the inoculation cell density was 1-2.5×10 4 / cm 2 Culture in an incubator at 37°C and 5% CO2.

[0112] 2. Small molecule compound treatment of bone marrow mesenchymal stem cells

[0113] The basal culture medium was replaced with a small molecule treatment solution, and the cells were cultured for 2-20 days. The small molecule treatment solution refers to: 10% fetal bovine serum (Hyclone) + 100U / ml penicillin (Sigma) + 100μg / ml streptomycin (Sigma) + high-glucose DMEM medium (Gibco) + 2 parts of curcumin, 1 part of forskolin, and 97 parts of a messenger carrier (including exosomes or liposomes formed by extrusion of human mesenchymal stem cells, messenger mRNA of SOX2 and messenger mRNA of Klf4), and the cells were cultured at 37°C and 5% CO2. In this culture system, 10% fetal bovine serum can also be replaced by a serum substitute (invitrogen) at a concentration of 10% to 20%; 100U / ml penicillin (Sigma) and 100μg / ml streptomycin (Sigma) can be omitted.

[0114] 3. Maintenance and culture of bone marrow mesenchymal stem cells

[0115] After the treatment in the second step, the basal culture medium is completely replaced, and the culture is maintained normally, and the cells are cultured at 37°C and 5% CO2. The basal culture medium is: 10% fetal bovine serum (Hyclone) + 100U / ml penicillin (Sigma) + 100μg / ml streptomycin (Sigma) + high-glucose DMEM, in which the 10% fetal bovine serum can also be replaced by a serum substitute (invitrogen) at a concentration of 10% to 20%; 100U / ml penicillin (Sigma) and 100μg / ml streptomycin (Sigma) can be omitted.

[0116] 4. Identification of cell characteristics after treatment

[0117] 4.1 When the cells were passaged to passage 12, the cells were stained and identified using the Bio-Tech Cell Senescence β-Galactosidase Staining Kit.

[0118] 4.2 When the cells were passaged to passage 12, they were stained with CD29-PE, CD90, CD73, CD34, and CD45 flow cytometry antibodies from ebioscience, and the corresponding isotype control from the same manufacturer was used as the control. The cells were analyzed on a BD JAZZ flow cytometer according to the manufacturer's instructions.

[0119] 4.3 When the cells were passaged to passage 12, osteogenic and adipogenic differentiation induction medium from Cyagen Biosciences was used for induction. The specific steps were in accordance with the product instructions.

[0120] 4.4 Cell proliferation detection, with 1.5x10 5 As the initial inoculum cell amount, cells were counted for 12 consecutive days, and each time point was repeated for 3 groups.

[0121] 4.5 When the cells were passaged to the 14th generation, DNA samples were collected and telomere length was detected using the Cawthon qPCR method, with Takara SYBR Green I as the fluorescent dye.

[0122] The telomere amplification primer sequences are

[0123] mTe1:CGGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT;

[0124] mTe1:GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT;

[0125] Single copy gene primers

[0126] 36B4-SF:CAGCAAGTGGGAAGGTGTAATCC;

[0127] 36B4-SR:CCATTCTATCATCAACGGGTACAA.

[0128] 4.6 When the cells were passaged to the 14th generation, RNA samples were collected and TERT was detected by PCR. The primer sequence of human TERT was

[0129] F:5'-CGGAAGAGTGTCTGGAGCAA-3;

[0130] R5′-GGATGAAGCGGAGTCTGGA-3′.

[0131] 4.7 When the cells were passaged to the 14th generation, RNA samples were collected, and the changes in the expression levels of genes TPP1, CDKN1A, ATF3, GADD45B, BTG2, H2AFX, ITGA6, and COL1A1 were quantified through transcriptome analysis.

[0132] 4.8 Allogeneic skin transplantation, detection of the immunomodulatory effect of human bone marrow mesenchymal stem cell culture fluid treated with small molecule compounds. The specific method is as follows: the experimental groups are small molecule compound treated cell group, untreated cell group, and PBS group. Among them, the 14th generation was passed down, and the animal experiment was performed in accordance with the requirements of the Animal Ethics Committee. The donor C57B / 6 mice were anesthetized, fixed in the supine position, and the whole back was depilated. The full layer of skin of 1.5cm x 1.5cm was taken from the back, and the subcutaneous fat and blood vessels were removed. The mouse skin was cut into skin pieces with a diameter of 1.0cm and placed in a plate containing sterile PBS for later use. The cut skin pieces were turned over and placed in a culture dish with saline. The subcutaneous tissue was gently cut to the dermis with a surgical blade, and then placed in sterile saline for later use.

[0133] The recipients were BALB / c mice. After anesthesia, the back hair was removed, the back skin was disinfected with iodine, a skin incision with a diameter of 1.0 cm was prepared, and the blood vessels were preserved. C57B / 6 skin grafts were transplanted in the reverse direction of the back hair, and the surface was covered with vaseline gauze and bandages with appropriate tightness. Within 1 hour after transplantation, the liquids of each group in the list were injected from the tail vein.

[0134] 4.9 Detection of cell clone formation rate: After the cells were subcultured to the 14th generation, cells in the logarithmic growth phase were selected and counted at 10 cells / cm 2 Plate the plates, set up 3 replicate wells for each group, change the medium every 2 days, stain with Giemsa or PI after 1 to 2 weeks, and count the number of clones formed under a microscope.

[0135] The operation of Example 2 was repeated twice to obtain two results, namely, the first Example 2 and the second Example 2.

[0136] Example 3

[0137] The small molecule compound treatment process of skin fibroblasts in Example 1 was replaced by:

[0138] Replace the basal culture medium with a small molecule treatment solution, and culture the cells for 2-20 days. The small molecule treatment solution refers to: 10% fetal bovine serum (Hyclone) + 100U / ml penicillin (Sigma) + 100μg / ml streptomycin (Sigma) + high-glucose DMEM medium (Gibco) + 2 parts of curcumin, 1 part of forskolin, and 97 parts of a messenger carrier (including exosomes or liposomes formed by extrusion of human mesenchymal stem cells, messenger mRNA of SOX2 and messenger mRNA of Klf4). In this culture system, 10% fetal bovine serum can also be replaced by a serum substitute (invitrogen) at a concentration of 10% to 20%; 100U / ml penicillin (Sigma) and 100μg / ml streptomycin (Sigma) can be omitted. Culture the cells at 37°C, 5% CO2.

[0139] The remaining steps are the same as those in Example 1.

[0140] Example 4

[0141] The small molecule compound treatment process of skin fibroblasts in Example 1 is replaced by:

[0142] Replace the basal culture medium with a small molecule treatment solution, and culture the cells for 2-20 days. The small molecule treatment solution refers to: 10% fetal bovine serum (Hyclone) + 100U / ml penicillin (Sigma) + 100μg / ml streptomycin (Sigma) + high-glucose DMEM medium (Gibco) + 5-Aza-2'-deoxycytidine (0.2-20μM). In this culture system, 10% fetal bovine serum can also be replaced by serum substitutes (invitrogen) at a concentration of 10%-20%; 100U / ml penicillin (Sigma) and 100μg / ml streptomycin (Sigma) can be omitted. Culture the cells at 37°C, 5% CO2.

[0143] The remaining steps are the same as in Example 1.

[0144] Among them, 5-Aza-2'-deoxycytidine refers to 5-aza-2-deoxycytidine, also known as deoxyazacytidine, decitabine and its intermediates (research and development), 5-aza-2'-deoxycytidine nucleoside, and decitabine.

[0145] Example 5

[0146] The small molecule compound treatment process of skin fibroblasts in Example 1 is replaced by:

[0147] Replace the basal culture medium with a small molecule treatment solution, and culture the cells for 2-20 days. The small molecule treatment solution refers to: 10% fetal bovine serum (Hyclone) + 100U / ml penicillin (Sigma) + 100μg / ml streptomycin (Sigma) + high-glucose DMEM medium (Gibco) + RG108 (0.5-30μM). In this culture system, 10% fetal bovine serum can also be replaced by serum substitutes (invitrogen) at a concentration of 10%-20%; 100U / ml penicillin (Sigma) and 100μg / ml streptomycin (Sigma) can be omitted. Culture the cells at 37°C, 5% CO2.

[0148] The remaining steps are the same as in Example 1.

[0149] Among them, RG108 is a non-nucleoside DNA methyltransferase inhibitor.

[0150] Experimental results:

[0151] 1. Morphological changes of human skin fibroblasts after the action of small molecule compounds. During the treatment, skin fibroblasts were cultured normally and passed to the 13th generation. Some fibroblasts that originally grew in a long spindle shape began to show aging conditions with enlarged cell volume and irregular cell shape. Using β-galactosidase staining, it can be seen that senescent cells are stained blue; after being treated with the methods in Examples 1 and 3, the cells of the 14th generation had a basically regular long spindle shape, and the β-galactosidase staining result was negative.

[0152] The changes in the morphology of human bone marrow mesenchymal stem cells after the action of small molecule compounds, when untreated, the mesenchymal stem cells were cultured normally, and when they reached the 10th generation, some cells that originally grew in a spindle shape became larger, the cells were elongated or grew irregularly, and β-galactosidase staining showed that senescent cells were stained blue; after treatment using the method in Example 2, the cells of the 12th generation had a basically regular spindle shape, and β-galactosidase staining showed a negative result.

[0153] It is shown that the small molecule compound of the present application can reverse the aging process of cells, tissues and organs of mammals and improve the repair capacity of human tissues and organs.

[0154] 2. Identification of the properties of human skin fibroblasts after the action of small molecule compounds. After treatment using the methods in Examples 1 and 3, the cells were able to express the molecular markers CD29 and vimentin of skin fibroblasts normally, just like before treatment. Among them, CD29 (integrinβ1) and vimentin are cytoskeleton and cell adhesion molecules, which play an important role in cell movement, differentiation, adhesion and signal transduction, respectively. Among them, CD29 is a cell surface adhesion molecule that participates in the interaction between cells and the extracellular matrix (ECM). By binding to ECM proteins (such as fibronectin and laminin), CD29 regulates cell migration, proliferation and differentiation. CD29 has the following relationship with proliferation ability: CD29 activation can promote cell adhesion and signal transduction, thereby affecting cell cycle and proliferation. For example, CD29 activation can promote cell proliferation through FAK (focal adhesion kinase) and PI3K / Akt signaling pathways. Vimentin is a kind of intermediate filament, mainly present in interstitial cells. It plays a key role in maintaining cell shape, cell movement and mechanical robustness. Vimentin has the following relationship with proliferation ability: Vimentin expression is associated with epithelial-mesenchymal transition (EMT), which is an important process for tumor cell proliferation and migration. High expression of Vimentin is usually associated with enhanced cell proliferation and migration ability.

[0155] At the same time, the proliferation ability of Fib-treated (fibroblast growth factor treated) after Example 1 is significantly improved compared with that of untreated Fib. This shows that the basic phenotypic characteristics and stem cell characteristics of the cells have not changed significantly regardless of treatment. The proliferation ability of MSC cells was effectively improved after treatment in Example 1. This may be because the treatment method activated certain proliferation-related signal pathways and increased the proliferation activity of the cells.

[0156] The characteristics of human bone marrow mesenchymal stem cells were identified after the action of small molecule compounds. The molecular markers of mesenchymal stem cells were expressed consistently before and after treatment, including positive CD29, CD90, CD73 and negative CD34 and CD45. The proliferation capacity of MSC-treated cells after treatment was significantly improved compared with that before treatment. The treated MSC cells were also able to undergo three lineage differentiation normally, and could achieve osteogenic and adipogenic differentiation of cells.

[0157] This shows that the basic phenotypic characteristics and stem cell properties of the cells did not change significantly regardless of treatment. However, the proliferation capacity of MSC cells was effectively improved after treatment in Example 2. This may be because the treatment method activated certain proliferation-related signal pathways and increased the proliferation activity of the cells.

[0158] 3. Changes in telomere length of human cells after the action of small molecule compounds. Taking human skin fibroblasts before treatment as a control, after treatment using the methods of Example 1, Example 3, Example 4, and Example 5, the telomere length increased and was greater than 1.5 times.

[0159] The changes in telomere length of human bone marrow mesenchymal stem cells after the action of small molecule compounds, with human bone marrow mesenchymal stem cells before treatment as a control, after treatment using the method of Example 2, the telomere length increased.

[0160] 4. Comparison of telomere length and age of human cells after the action of small molecule compounds, and the expression of telomere-related genes: Compared with the average telomere length of healthy people of about 35 years old, and compared with the autologous body, the telomere length of skin fibroblasts from a 52-year-old individual increased significantly after treatment with a small molecule combination, and the gene TPP1 related to telomere extension was transiently highly expressed, and TERT (telomerase reverse transcriptase) was transiently expressed in immortalized cells 293T, Fib on Day 12 (human skin fibroblasts, human skin fibroblasts before treatment in Example 1), and MSC on Day 12 (human bone marrow mesenchymal stem cells; human bone marrow mesenchymal stem cells before treatment in Example 2).

[0161] 5. Changes in the expression of aging-related genes in human skin fibroblasts after the action of small molecule compounds. In the treated cells, aging-related genes were all downregulated, such as the genes CDKN1A, ATF3, GADD45B, BTG2 related to the P53 tumor suppressor pathway and the aging-related H2A histone family member X.

[0162] 6. Detection of in vitro functional activity of human skin fibroblasts after the action of small molecule compounds: As in Example 1, type I collagen of skin fibroblasts was significantly upregulated after treatment; ITGA6, a marker of early developmental skin cells, was significantly upregulated after treatment.

[0163] 7. Detection of the in vivo functional activity of human skin fibroblasts after the action of small molecule compounds: Fibroblasts isolated from the skin have weak immunoregulatory ability. After the cells were treated by the methods of Example 1 and Example 2, in the allogeneic skin transplantation model, the culture medium after the cells were cultured for 48 hours was injected into the recipient mouse, and the skin transplantation site was observed after 8 days. Compared with the control group (untreated cell group Fib, PBS group, cells not treated by Example 1 and Example 2 were used as the control group, respectively), the donor transplanted skin received less immune rejection reaction, and the treated cells had obvious systemic immunoregulatory effect.

[0164] 8. Results of the detection of stemness and tumorigenicity of cells cultured for a long time after the action of small molecule compounds: The cells treated in Example 1 were transplanted subcutaneously into Nod-SCID mice, and no tumor formation was observed after 28 days; the stemness gene OCT4 was stained for this group of cells, and no expression was observed.

[0165] The cells treated in Example 2 were transplanted subcutaneously into Nod-SCID mice, and no tumor formation was observed after 28 days. The stemness gene OCT4 was stained for this group of cells, and no expression was observed.

[0166] 9. After the molecular compound acts on the human skin fibroblasts in Example 1, the number of clones formed is higher than before the treatment, showing the clone morphology formed. Before the treatment, the clones of cells (Fib) are smaller and the cells are dispersed; while the morphology of the treated cells (Fib-treated) is compact.

[0167] The number of clones formed by the bone marrow mesenchymal stem cells in Example 2 after the molecular compound was treated was higher than that before treatment, showing the clone morphology formed. Before treatment, the clones of cells were smaller and the cells were dispersed; while the morphology of the treated cells was compact.

[0168] This application uses small molecule compounds or their combinations to prevent, delay or reverse the aging of cells, tissues, organs, and organisms, and prolong the length of cell telomeres. The target of action is clear, the ingredients are clear, mature and stable, and the anti-aging process can be accurately regulated; and small molecule compounds are easy to control quality and mass produce. Since the body or cells do not express stemness genes during the action process, the safety is high; and small molecule compounds and their combinations are easily absorbed by the body, and can prevent, delay and reverse aging at the overall level of cells, tissues, organs, and organisms, which is of great significance to delaying the human aging process, improving health status and quality of life.

[0169] It can be understood that the above embodiments only express the preferred implementation modes of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the patent scope of the present invention. It should be pointed out that, for ordinary technicians in this field, the above technical features can be freely combined without departing from the concept of the present invention, and several deformations and improvements can be made, which all belong to the protection scope of the present invention. Therefore, all equivalent changes and modifications made to the scope of the claims of the present invention should belong to the coverage of the claims of the present invention.

Claims

1. A small molecule compound, characterized in that: The invention comprises the following components in weight fractions: 2-4 parts of curcumin, 1-2 parts of forskolin, and 96-98 parts of a messenger carrier; the messenger carrier comprises exosome-like or liposome-like formed by extrusion of human mesenchymal stem cells, messenger cRNA of SOX2 or messenger cRNA of Klf4, wherein the messenger cRNA of SOX2 or messenger cRNA of Klf4 is loaded inside the exosome-like or liposome-like formed by extrusion of human mesenchymal stem cells.

2. A small molecule compound according to claim 1, characterized in that: The weight ratio of curcumin to forskolin is 2:

1.

3. A small molecule compound according to claim 1, characterized in that: The human mesenchymal stem cells include human adipose-derived mesenchymal stem cells, human umbilical cord-derived mesenchymal stem cells or human bone marrow-derived mesenchymal stem cells.

4. A small molecule compound according to claim 1, characterized in that: The CDS sequence of the messenger cRNA of SOX2 is shown in SEQ ID NO.

1.

5. A small molecule compound according to claim 1, characterized in that: The CDS sequence of the Klf4 messenger cRNA is shown in SEQ ID NO.

2.

6. An anti-aging preparation, characterized in that: A small molecule compound comprising any one of claims 1 to 5.

7. An anti-aging preparation according to claim 6, characterized in that: The preparation includes one or more of a preparation box, a culture solution, a culture medium, a medicine, a health product, a food, a cosmetic, and a medical device containing the small molecule compound.

8. An application of a small molecule compound, characterized in that: A small molecule compound as described in any one of claims 1 to 5 is used to improve the tissue and organ repair ability of mammals.

9. An application of a small molecule compound, characterized in that: A small molecule compound as described in any one of claims 1 to 5 is used to reverse the aging process of cells, tissues and organs of mammals.

10. An application of a small molecule compound, characterized in that: A small molecule compound according to any one of claims 1 to 5 is used to increase the telomere length of mammalian cells.